We can’t show the full text here under this license.
Abstract
Heart failure with preserved ejection fraction () is the leading form of heart failure worldwide.
- Diabetes mellitus (DM) is associated with an increased risk of developing HFpEF.
- The combination of HFpEF and DM may further deteriorate cardiovascular health and accelerate diabetes progression.
- Novel antidiabetic drugs, including sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase 4 inhibitors (DPP4i), have shown cardiovascular benefits in Type 2 diabetes patients with HFpEF.
- The specific roles and mechanisms of these antidiabetic drugs in treating diabetic HFpEF are not fully understood.
- A comprehensive understanding of diabetic HFpEF could provide new insights into its treatment.
Simplified